Immunotherapy Program with PD-1 Inhibitor
What's included in this package
Medical Procedures
- Immunotherapy
- 24-hr nurse services
Duration
Accommodation
Accommodation is not included
Transport
Transfer is not included
Additional information
This treatment uses a PD-1 inhibitor to help the immune system recognize and attack cancer cells. The therapy may be recommended for patients with certain types and stages of cancer, depending on their diagnosis and biomarker results.
The treatment plan is individually selected by the oncologist based on the patient's medical history, previous treatments, and test results.
Package includes:
Oncology consultation
Treatment planning
PD-1 inhibitor therapy
Necessary monitoring during treatment
The treatment plan is individually selected by the oncologist based on the patient's medical history, previous treatments, and test results.
The exact medication, number of treatment cycles, and final cost are determined after medical evaluation.
24/7 Bookimed assistance
- Personal medical coordinator
- Medical travel arrangements — booking of air tickets and hotel rooms at special partner prices
- Patient advocacy during medical travel
Program price
special price valid till October 23, 2026
What's NOT included in this package
Doctor
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
How are we doing?
About the clinic
Uni-asia Cancer Hospital is a private single-specialty medical center located in Chengdu, China, dedicated to oncology and phlebology, including interventional therapy for liver cancer. A 9-year-old patient with liver cancer achieved complete recovery following interventional therapy at the hospital.
Uni-asia Cancer Hospital serves both adults and children and treats 20,000 patients every year, with patients coming most often from Arab League states, Asia, and Russian-speaking countries.
Payment & Rewards
You don’t pay for our services
You make your payment directly at the clinic or to their official bank account.
Some clinics may require a deposit as a part of their policy.
Spread out your payments with installment options.
Earn rewards for referring friends to Bookimed.